Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research focused on Refractory (planetary science) and Follicular lymphoma, with related work in Oncology, Diffuse large B-cell lymphoma, Cohort. Notable publications include 'Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial', 'Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study', and 'Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial'.
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Phase I/IIa clinical study of 4th generation BTK inhibitor HBW-3220 capsules in patients with B-cell malignancies.
Clinical Risk Stratification and Modifiable Risk Factors for Hepatitis B Virus-Related Follicular Lymphoma
Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study
Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study
Time to lymphoma treatment within 24 months in ‘watch and wait’ follicular lymphoma is associated with inferior outcomes: A multicentre analysis
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study